Clinical trials: BRCA2 Gene Mutation
Ovarian Neoplasms, Fallopian Tube Neoplasms
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
Niraparib is an oral, potent and highly selective PARP1/2 inhibitor. It can be used as a single drug in HRD positive ovarian cancer patients for multi-line therapy.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Endocrine Gland Neoplasms, Neoplasms by Site
- Trial name
- AVANIRA3 (NCT04556071)
- Testing
- Niraparib, Bevacizumab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Xiaoxiang Chen
Breast Cancer, BRCA1 Mutation
Depression and Body Image Distress Following Mastectomy With Reconstruction
Mastectomy is a major surgery that can have a profound effect on women's psychosocial wellbeing, including elevated depression and body image distress.
- Conditions
- Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
- Trial name
- NCT03428399
- Testing
- Psychosocial variables
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Massachusetts General Hospital
Pancreas Cancer, Pancreatitis
Pancreas Registry and High Risk Registry
The purpose of this study is to establish a registry of patients with pancreatic diseases. Patients included in the registry may include those with: pancreatic cancer, precancerous lesions of the pancreas, inflammatory lesions of…
- Conditions
- Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst
- Trial name
- NCT02775461
- Where
- 2 sites in United States
- Volunteers
- 1,368 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
brca1 Mutation Carrier, brca2 Mutation Carrier
Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of fenretinide may prevent ovarian cancer.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
- Trial name
- NCT00098800
- Testing
- fenretinide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Arizona
Prostate Cancer Metastatic, Prostate Cancer Recurrent
Molecular Profiling in Prostate Cancer
We aim to employ targeted DNA NGS to evaluate the prevalence of germline and somatic mutations in cancer predisposing genes, such as BRCA1 and BRCA2, and other HR and DDR genes, including also a few additional clinically relevant…
- Conditions
- Prostate Cancer Metastatic, Prostate Cancer Recurrent, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation
- Trial name
- ProProstate (NCT04983628)
- Testing
- Tumor molecular profiling
- Where
- Greece
- Volunteers
- 250 people
- Sponsor
- Hellenic Cooperative Oncology Group
Familial Pancreatic Cancer, BRCA1 Mutation
Registry of Subjects at Risk of Pancreatic Cancer
IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.
- Conditions
- Familial Pancreatic Cancer, BRCA1 Mutation, BRCA2 Mutation, Lynch Syndrome
- Trial name
- IRFARPC (NCT04095195)
- Testing
- MRCP, Endoultrasonography
- Where
- 4 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Associazione Italiana per lo Studio del Pancreas
High Grade Serous Carcinoma, Triple Negative Breast Cancer
Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
The purpose of this Phase I study is to determine if the PARP inhibitor olaparib can be safely combined with navitoclax, an inhibitor of Bcl-2/Bcl-XL, in women with TNBC who have somatic or germline mutations in breast cancer…
- Conditions
- High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer
- Trial name
- NCT05358639
- Testing
- Olaparib tablet, Navitoclax
- Where
- 3 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Sunnybrook Health Sciences Centre
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase Ib trial studies the best dose and side effects of niraparib and copanlisib in treating patients with endometrial, ovarian, primary peritoneal, or fallopian tube cancer that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma
- Trial name
- NCT03586661
- Testing
- Copanlisib, Niraparib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
ATM Gene Mutation, BRCA1 Gene Mutation
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to…
- Conditions
- ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone
- Trial name
- NCT03442556
- Testing
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Washington
Pancreatic Cancer
Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene
Patients will be tested for mutations in the BRCA2 gene. If they have a BRCA2 mutation, they will be treated with Mitomycin-C as described here.
- Trial name
- NCT00386399
- Testing
- Mitomycin-C
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ovarian Cancer, Peritoneal Cancer
Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
This research study is a way of gaining new knowledge about a drug called olaparib in women who have either: 1)never received a PARP inhibitor before to treat ovarian cancer (group 1) or 2)participants who have received a PARP…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01661868
- Testing
- Olaparib
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
The researchers are doing this study to look at changes in Ki67 expression after at least 2 weeks of endocrine therapy in people with ER+/HER2- breast cancer undergoing cancer removal surgery.
- Trial name
- NCT06127979
- Testing
- blood draw
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS)
The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
- Conditions
- Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier
- Trial name
- CAPS5 (NCT02000089)
- Testing
- Secretin, MRI, Tumor marker gene test with CA19-9
- Where
- 9 sites in United States
- Volunteers
- 9,000 people
- Sponsor
- Johns Hopkins University
To Determine the Prevalence, Penetrance of BRCA1 and BRCA2 Mutations in Romanian Womens With Breast or Ovarian Cancer
BRCA1 and BRCA2 Mutation in Romanian Population: a Study of Genotype - Phenotype Correlation at Diagnosis With Prospective Disease Outcome and Survival
Primary objective To determine BRCA1 and BRCA2 variants in 250 Romanian women with breast/ovarian cancer selected for likeliness to harbor germline mutations in these genes by specific criteria for high-risk status including age…
- Trial name
- NCT02317120
- Testing
- NGS BRCA 1 and BRCA 2 full sequencing, Multiplex ligation-dependent probe amplification (MPLA) BRCA1 BRCA2
- Where
- Romania
- Volunteers
- 250 people
- Sponsor
- Alexandru Eniu
Breast Cancer
Adherence to Intensive Surveillance for Hereditary Breast Cancer
Women with strong family histories of breast cancer are at increased risk to have breast cancer. Women whose close relatives have had breast cancer often have more breast cancer screening than other women their age.
- Trial name
- NCT00582803
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
hCG, BRCA1 Mutation
Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers
Specific aim: To establish the proof of principle that treatment of "high breast cancer risk" women with recombinant human chorionic gonadotropin (r-hCG) will change their breast epithelium's high risk genomic profile to one…
- Conditions
- hCG, BRCA1 Mutation, BRCA2 Mutation
- Trial name
- NCT03495609
- Testing
- Ovitrelle
- Where
- Belgium
- Volunteers
- 33 people
- Sponsor
- University Hospital, Ghent
Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer.
- Conditions
- Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma
- Trial name
- SHARON (NCT04150042)
- Testing
- Melphalan, BCNU, Vitamin B12B
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- General Oncology, Inc.
BRCA1 Syndrome, BRCA2 Syndrome
Prostate Cancer Screening Among Men With High Risk Genetic Predisposition
This will be a prospective diagnostic trial of screening for prostate cancer among men with genetic predisposition.
- Conditions
- BRCA1 Syndrome, BRCA2 Syndrome, Lynch Syndrome
- Trial name
- NCT02053805
- Testing
- PSA, IPSS questionnaire, DRE (Digital Rectal Examination )
- Where
- 2 sites in Israel
- Volunteers
- 200 people
- Sponsor
- Rabin Medical Center
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Cancer Prevention in Women With a BRCA Mutation
This study aims to develop a follow-up telephone-based genetic counselling (FTGC) intervention for women with a BRCA1 or BRCA2 mutation who have received genetic counseling in the past.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Cancer, Ovarian Cancer
- Trial name
- NCT02225015
- Testing
- Follow-up Telephone Genetic Counselling
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- Women's College Hospital
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel…
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- ERADIC8 (NCT06395519)
- Testing
- ETX-19477
- Where
- 14 sites in United States
- Volunteers
- 120 people
- Sponsor
- 858 Therapeutics, Inc.